NBIX

Neurocrine Biosciences Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth 5/10
  • Momentum 4/10
Neurocrine Biosciences sales and earnings growth
NBIX Growth
Neutral
  • Revenue Y/Y 21.45%
  • EPS Y/Y 41.47%
  • FCF Y/Y 34.37%
Neurocrine Biosciences gross and profit margin trends
NBIX Profitability
Great
  • Gross margin 98.20%
  • EPS margin 16.70%
  • ROIC 20.00%
Neurocrine Biosciences net debt vs free cash flow
NBIX Risk
Great
  • Debt / Equity 0.1
  • Debt / FCF 0.0
  • Interest coverage NA

Neurocrine Biosciences stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗